Clinical Lymphoma, Myeloma & Leukemia, Vol.22, Suppl.2 - October 2022

S33 US, second AHCT at the time of relapse can provide durable responses particularly in patients with long interval since first AHCT and patients who were not receiving maintenance therapy. Salvage AHCT is also appealing in regions with limited or no availability of novel anti-MM agents. Efforts are needed to refine the conditioning regimen and post salvage AHCT maintenance therapy in order to make it more helpful and better define its role in modern MM care. References 1. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 201 7 ;3 7 6(14):1311-1320. 2. Perrot A, Lauwers-Cances V, Cazaubiel T, et al. Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial. Blood. 2020;136(Supplement 1):39-39. 3. Gay F, Musto P, Rota-Scalabrini D, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021;22(12):1 7 05-1 7 20. 4. Cook G, Ashcroft AJ, Cairns DA, et al. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016;3( 7 ):e340-351. 5. Goldschmidt H, Baertsch MA, Schlenzka J, et al. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia. 2021;35(4):1134-1144. 6. Yarlagadda L, Gundarlapalli S, Parikh R, et al. Salvage Autologous Stem Cell Transplantation in Daratumumab- Refractory Multiple Myeloma. Cancers (Basel). 2021;13(16). 7 . Farag S, Jeker B, Bacher U, et al. Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients. Hematol Oncol. 2018;36(4):6 7 1-6 7 8. 8. Nieto Y, Valdez BC, Pingali SR, et al. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet Haematol. 201 7 ;4(6):e283-e292. 9. Costa LJ, Landau HJ, Chhabra S, et al. Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. Biol Blood Marrow Transplant. 2018;24( 7 ):13 7 9-1385.